AbbVie Reports First-Quarter 2023 Financial Results : vimars

Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These...

Related Keywords

United States , American , Richarda Gonzalez , Lumigan Ganfort , Linzess Constella , Alphagan Combigan , Abbvie Inc , Drug Administration , Colitis Organisation , Exchange Commission , Capsida Biotherapeutics Inc , American Academy Of Dermatology , Twitter , European Union , Janssen Biotech Inc , European Commission , Allergan , Boehringer Ingelheim , Reports First Quarter Diluted , Adjusted Diluted , These Results Include , Unfavorable Impact , Milestones Expense , First Quarter Net Revenues , Reported Basis , Quarter Global Net Revenues , Immunology Portfolio Were , Operational Basis , Global Humira Net Revenues Were , Global Skyrizi Net Revenues Were , Global Rinvoq Net Revenues Were , Hematologic Oncology Portfolio Were , Global Imbruvica Net Revenues Were , Global Venclexta Net Revenues Were , Neuroscience Portfolio Were , Global Botox Therapeutic Net Revenues Were , Global Vraylar Net Revenues Were , Aesthetics Portfolio Were , Global Botox Cosmetic Net Revenues Were , Global Juvederm Net Revenues Were , Share Related , Milestones Expense Incurred During , First Quarter , Botox Therapeutic , Botox Cosmetic , Janus Kinase , Tyrosine Kinase , European Crohn , Annual Meeting , Janssen Biotech , Complete Response Letter , New Drug Application , Allergan Aesthetics , Investor Relations , Private Securities Litigation Reform Act , Quarterly Reports , Ended March , Abbvie ,